RAPT Therapeutics, Inc. (RAPT)

In August 2025, RAPT Therapeutics reported its second-quarter financial results. In October 2025, the company reported positive Phase 2 CSU data for ozureprubart and completed an underwritten public offering, raising approximately $250.0 million. In November 2025, RAPT Therapeutics reported its third-quarter financial results. In January 2026, GSK announced an agreement to acquire RAPT Therapeutics for approximately $2.2 billion. Following the acquisition announcement, several analysts downgraded RAPT's stock, and legal firms initiated investigations. In February 2026, RAPT Therapeutics' stock hit a new 52-week high, and the company received a consensus "Hold" rating from analysts.

As a clinical-stage biopharmaceutical company, Rapt Therapeutics, Inc. does not currently have commercialized products on the market, so there is no information available regarding demand seasonality. The company's revenue is primarily derived from collaboration and licensing agreements and capital raises.

Rapt Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel oral small-molecule therapies for patients with unmet needs in inflammatory and immunologic diseases, as well as oncology. Ozureprubart is in clinical development for food allergy, chronic spontaneous urticaria (CSU), and allergic asthma. Tivumecirnon is in clinical trials for various cancer indications, including advanced head and neck squamous cell carcinoma (HNSCC). RPT193 is in clinical development for atopic dermatitis and allergic asthma.

Rapt Therapeutics is headquartered in South San Francisco, California, and also has operations in San Diego, California. The company has expanded its operations across the United States and leverages partnerships and collaborations to extend its global reach. RAPT has a partnership with Shanghai Jeyou Pharmaceutical Co., Ltd. for global development and commercialization rights for ozureprubart outside of the Chinese mainland, Hong Kong, Macau, and Taiwan.

Rapt Therapeutics' brand reputation has been influenced by its clinical progress and the recent acquisition announcement. The positive Phase 2 data for ozureprubart in CSU likely bolstered its scientific and development reputation. The acquisition agreement by GSK, while leading to a significant stock price increase, also triggered analyst downgrades and investigations by legal firms. The company generally maintains a "Hold" consensus rating from analysts.

Rapt Therapeutics' ownership is primarily concentrated among institutional investors, who hold approximately 82.07% of the shares. Major institutional holders include OrbiMed Advisors, TCG Crossover Management, Medicxi Ventures, and Vanguard Group Inc. Retail and public float account for about 17.51% of shares, while company insiders hold a small fraction, around 0.42%.